ClinicalTrials.gg
RecruitingNCT06670521COPEDUpdated May 6, 2026

Corticosteroids for Post-Extubation Dysphagia

A Phase 2 interventional study of Methylprednisolone and Normal Saline in Dysphagia and Laryngeal Edema, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Deglutition Disorders with a site in United States — 43 open to participants now, 48 under way, none of them phase 3. Deglutition Disorders · United States.

Planned enrollment
53rd of 165
80 · median 50
Started
2024
with 13 others
Phase 2
18 of 230
4 open now
Primary completion
2026-11
later than 14 of 47 live
Registered
208th of 230
by date

Among the 230 studies in Deglutition Disorders with a site in United States, this one is the 53rd largest by planned enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 14 of the 47 other live ones, and was the 208th registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

43 of the 230 studies in Deglutition Disorders with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Deglutition Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure COMIRB # 21-3873, study design, and research methods. Patients for the study proposed will have already been enrolled in the R01 longitudinal cohort study. The sites to perform this study include Colorado, BU, Yale, Tufts, and Stanford. Those R01-enrolled patients with laryngeal edema on their initial FEES examination: defined as the revised Patterson edema score greater than zero, will be approached for enrollment.

Read the detailed description

This is a multicenter study conducted across the University of Colorado, Boston University, Stanford University, Tufts Medical Center, and Yale University. The study aims to enroll a total of 80 participants, with approximately 20 participants at each site. This study aims to investigate the effects of intravenous corticosteroids on laryngeal edema and swallowing function in survivors of acute respiratory failure (ARF) who have documented laryngeal edema. It evaluates whether administering corticosteroids can reduce edema and improve quality of life related to swallowing after hospital discharge. The study includes ARF survivors with confirmed laryngeal edema, who will be randomized into two groups. Patients in the intervention group will receive 50 mg of methylprednisolone intravenously every six hours for a total of four doses, amounting to 200 mg (equivalent to 1,000 mg of hydrocortisone), while the control group will receive a saline placebo intravenously under the same regimen.

The primary outcomes of the study focus on measuring the reduction in laryngeal edema post-treatment and evaluating post-extubation swallowing function. Secondary outcomes include assessing quality of life one month after hospitalization, particularly regarding swallowing function and the ability to return to pre-hospitalization dietary habits. To measure laryngeal edema, the Revised Patterson Edema Scale will be utilized, which assesses edema across eight specific regions of the upper airway (such as the epiglottis and vallecula). Each area is rated on a scale from 0 to 3, resulting in an overall score ranging from 0 (normal) to 24 (severe edema). This scale has been adapted for the study to enhance sensitivity and reliability, showing moderate to good interrater reliability across assessed areas.

Participants will be randomized in a 1:1 ratio using a permuted block randomization method to ensure balanced allocation. The findings from this study could have significant implications for post-extubation care in ARF survivors, potentially guiding clinical practices for managing laryngeal edema and improving patients' swallowing function and overall quality of life after hospitalization.

03

Conditions studied

  • Dysphagia
  • Laryngeal Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant enrolled in primary study COMIRB #21-3873/ NCT # 05108896
  • Laryngeal edema identified on participants primary study Fiberoptic Endoscopic Evaluation of Swallowing (FEES) as defined as a revised Patterson edema score greater than zero
  • Admission to an ICU during their hospitalization
  • Mechanical ventilation with an endotracheal tube for greater than 48 hours.
  • Extubation except for compassionate extubation or transition to end-of-life care.

Exclusion criteria

Exclusion Criteria:

  • Patient or provider refusal
  • or defined as an allergic reaction (extremely rate) or taking other medications.
  • Chronic treatment with corticosteroids (>= 40 mg Prednisone/day, >=32 Methylprednisolone/day)
  • Contraindication to enteral/oral nutrition administration.
  • Pre-existing history of dysphagia or aspiration.
  • Pre-existing or acute primary central or peripheral neuromuscular disorder.
  • Presence of a chronic tracheostomy (present prior to ICU admission).
  • Pre-existing head and neck cancer or surgery.
  • Coagulopathy resulting in uncontrolled nasal or pharyngeal bleeding.
  • Delirium as assessed by CAM-ICU
  • Inability to obtain from patient or an appropriate surrogate.
  • Age \<18 years.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Corticosteroid Intervention

    50 mg Methylprednisolone IV every 6 hours for 4 doses (total dose 200mg)

    Drug: Methylprednisolone

  • Placebo comparator
    Placebo Control

    Normal Saline placebo dose IV every 6 hours for 4 doses

    Drug: Normal Saline

Interventions

  • 50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema

  • DrugNormal Saline

    Normal Saline placebo IV every 6 hours for 4 doses

06

What researchers measure

Primary outcomes

  1. Pre/post intervention change in the revised Patterson edema scale on FEES exam

    Investigators hypothesize that corticosteroids will be more effective (a larger pre/post reduction in the revised Patterson Edema scale) for resolution of swallowing dysfunction in patients recovering from acute respiratory failure with the presence of laryngeal edema on a FEES examination. Change is defined as the pre-study total FEES revised Patterson Edema scale minus the post-study total FEES revised Patterson Edema scale. Improvement in the total revised Patterson Edema scale would a positive number. For example, the pre-study total score was 15, the post-study total score was 8; therefore, the change would be a score of 7. Improvement in the total revised Patterson Edema scale would a positive number

    Time frame: Day 1 through Day 5

Secondary outcomes

  1. Change in Individual Components of the Revised Patterson Edema Scale

    Since there is variability in the amount of edema in the eight different locations of the revised Patterson edema scale, investigators will examine the effect of corticosteroids compared to placebo on the change in edema in each of these eight areas. Change is defined as the pre-study FEES revised Patterson Edema scale minus the post-study FEES revised Patterson Edema scale. The scale assesses eight areas of the upper airway (epiglottis, vallecula, pharyngoepiglottic folds, aryepiglottic folds, arytenoids, false vocal cords, true vocal cords, and pyriform sinuses) using a normal, mild, moderate, or severe scale. For this proposal, we have adapted this rating system to a 0-3 scale (normal =0 and severe = 3) for each of the eight locations in the upper airway. The overall score can range from 0 (normal) to 24 (severe edema in all 8 areas). The overall interrater reliability of the revised Patterson scale maintains moderate-good agreement for each of the eight upper airway locations.

    Time frame: Day 1 through Day 5

  2. Change in the Penetration-Aspiration Scale (PAS) Score

    Investigators will determine whether the administration of corticosteroids results in improvement in the severity of dysphagia and aspiration. The PAS score is a validated measure of the degree of aspiration on FEES of the visualized swallowed bolus. A PAS score of 2-5 defined penetration of the bolus into the laryngeal area above the vocal cords but without entering the airway. A PAS score of 6 or greater defines as aspiration. A PAS score of 6-7 represents non-silent aspiration, and a score of 8 represents silent aspiration. Investigators will determine a PAS score for each bolus during the two FEES examinations.

    Time frame: Day 1 through Day 5

Other outcomes

  1. Return to Pre-Hospitalization Diet

    Participants will be contacted by telephone one month after hospital discharge to assess their return to Pre-Hospitalization Diet. A pre-hospitalization diet has already been established in the primary study, 21-3873. Study personnel will ask participants about their current diet post-discharge. Returning to the pre-hospitalization diet will be defined as resuming the same diet they followed before hospitalization.

    Time frame: 1 month post-hospital discharge

  2. Post-Discharge Eating Assessment Tool (EAT-10)

    Participants will be contacted by telephone one month after hospital discharge to complete dysphagia screening tool to identify people at high risk of swallowing disorders. Each item corresponds to 5 difficulty levels from "no problem" to "serious problem," with a total score of 0 to 40. EAT-10 has good internal consistency and intraclass correlation coefficients (ICCs).

    Time frame: 1 month post-hospital discharge

  3. Post-Discharge Positive and Negative Affect Schedule (PANAS-SF)

    Participants will be contacted by telephone one month after hospital discharge to complete 20-item questionnaire to assess positive affect (PA) and negative affect (NA). PA is associated with pleasurable engagement with the environment, whereas NA reflects a dimension of general distress summarizing a variety of negative states such as anger, guilt, or anxiety. Positive Affect Score: Add the scores on items 1, 3, 5, 9, 10, 12, 14, 16, 17, and 19. Scores can range from 10 - 50, with higher scores representing higher levels of positive affect. Mean Scores: 33.3 (SD±7.2) Negative Affect Score: Add the scores on items 2, 4, 6, 7, 8, 11, 13, 15, 18, and 20. Scores can range from 10 - 50, with lower scores representing lower levels of negative affect. Mean Score: 17.4 (SD ± 6.2)

    Time frame: 1 month post-hospital discharge

  4. Post-Discharge Caregiver Assistance Scale (CAS)

    Participants will be contacted by telephone one month after hospital discharge to complete an assessment tool to collect data on how much assistance the caregiver provides to the participant for various activities over the past month. A rating of zero (0) indicates "no" assistance is provided, while a rating of six (6) indicates "a lot" is provided.

    Time frame: 1 month post-hospital discharge

  5. Post-Discharge Caregiving Impact Scale (CIS)

    Participants will be contacted by telephone one month after hospital discharge to complete an assessment tool to measure how much the participant's caregiver responsibilities interfere with different aspects of their life in their current living situation. Scoring ranges from zero (0), "Not at all" to six (6), "Very Much". If an item is not applicable, please circle zero (0) to indicate this.

    Time frame: 1 month post-hospital discharge

  6. Post-Discharge 20-Item Medical Outcomes Study (MOS) Social Support Survey

    Participants will be contacted by telephone one month after hospital discharge to complete this survey to measure the availability of support for the participant in several domains. The survey comprises of 4 subscales and one overall summary index. The subscales include emotional/informational support, tangible support, affectionate support, and positive social interaction. The summary score is the overall social support. Scoring ranges from (1) "None of the time to" (6) "All of the time" for each domain.

    Time frame: 1 month post-hospital discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Nov 1, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 31, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670521
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Dec 2, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Anna Matheson, BSN
Contact
anna.matheson@cuanschutz.edu
4848836222
Jeffrey McKeehan, MSN
Contact
jeffrey.mckeehan@cuanschutz.edu
3037246080
Marc Moss, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion